Related Experiment Videos
Does methotrexate increase the risk of infection or malignancy?
1Department of Medicine, University of South Florida School of Medicine, Tampa, USA.
Rheumatic Diseases Clinics of North America
|November 15, 1997
Summary
Methotrexate (MTX) effectively treats immune-mediated diseases, with a small increased risk of infections and potential malignancy. The clinical benefits generally outweigh these minor risks for patients.
Area of Science:
- Immunology and Pharmacology
- Oncology
- Infectious Diseases
Background:
- Methotrexate (MTX) is a widely used therapeutic agent for various immune-mediated diseases.
- Understanding the safety profile of MTX, including risks of infection and malignancy, is crucial for patient management.
Purpose of the Study:
- To evaluate the safety of methotrexate (MTX) in patients with immune-mediated diseases.
- To assess the risks of infection and malignancy associated with MTX therapy.
Main Methods:
- Review of existing studies and cited literature regarding MTX use in immune-mediated diseases.
- Analysis of reported infection rates and carcinogenicity data in patients treated with MTX.
Main Results:
- Most patients on MTX do not show overt immunosuppression.
- A modest increase in bacterial respiratory and skin infections was observed.
- Opportunistic infections are rare but can be life-threatening.
- The link between MTX and carcinogenicity, particularly non-lymphoproliferative malignancies, remains unclear, though sporadic cases have been reported.
Conclusions:
- Methotrexate (MTX) offers significant clinical benefits for immune-mediated diseases.
- The risks of infection and potential malignancy with MTX are generally small when weighed against its therapeutic advantages.